Evidence map›Paper›PMID 16776831›Full record

ArticleBMC pharmacology2006

Identification of specific calcitonin-like receptor residues important for calcitonin gene-related peptide high affinity binding.

Sugato Banerjee, Janel Evanson, Erik Harris, Stephen L Lowe, Kathryn A Thomasson, James E Porter

Open access · hybridAbstract read
In one paragraph

Article in BMC pharmacology, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 25 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Sugato BanerjeeDepartment of Pharmacology, Physiology & Therapeutics, School of Medicine & Health Sciences, University of North Dakota, Grand Forks, ND 58202-9037, USA. sbanerjee@medicine.nodak.edu
Janel Evanson
Erik Harris
Stephen L Lowe
Kathryn A Thomasson
James E Porter
University of North Dakota · US

Funding

TRPC1, CALCIUM AND PARKINSON'S DISEASEP20RR017699 · NCRR · UNIVERSITY OF NORTH DAKOTA · PI GROVE, BRYON D · 2002 to 2011
$19.7M
Inflammatory Signaling Mechanisms of the CGRP ReceptorR21DK062865 · NIDDK · UNIVERSITY OF NORTH DAKOTA · PI PORTER, JAMES · 2003 to 2004
$280k
Molecular Mechanisms Critical to CGRP Receptor SignalingR15GM066726 · NIGMS · UNIVERSITY OF NORTH DAKOTA · PI PORTER, JAMES · 2003 to 2003
$140k
NCRR NIH HHS 5P20RR017699NCRR NIH HHS P20RR016741NCRR NIH HHS P20 RR017699NIDDK NIH HHS 5R21DK62865NIDDK NIH HHS R21 DK062865NIGMS NIH HHS 1R15GM66726NIGMS NIH HHS R15 GM066726
6 · The paper itself

Abstract

backgroundCalcitonin gene-related peptide (CGRP) is a vasoactive neuropeptide whose biological activity has potential therapeutic value for many vascular related diseases. CGRP is a 37 amino acid neuropeptide that signals through a G protein-coupled receptor belonging to the secretin receptor family. Previous studies on the calcitonin-like receptor (CLR), which requires co-expression of the receptor-activity-modifying protein-1 (RAMP1) to function as a CGRP receptor, have shown an 18 amino acid N-terminus sequence important for binding CGRP. Moreover, several investigations have recognized the C-terminal amidated phenylalanine (F37) of CGRP as essential for docking to the mature receptor. Therefore, we hypothesize that hydrophobic amino acids within the previously characterized 18 amino acid CLR N-terminus domain are important binding contacts for the C-terminal phenylalaninamide of CGRP.

resultsTwo leucine residues within this previously characterized CLR N-terminus domain, when mutated to alanine and expressed on HEK293T cells stably transfected with RAMP1, demonstrated a significantly decreased binding affinity for CGRP compared to wild type receptor. Additional decreases in binding affinity for CGRP were not found when both leucine mutations were expressed in the same CLR construct. Decreased binding characteristic of these leucine mutant receptors was observed for all CGRP ligands tested that contained the necessary amidated phenylalanine at their C-terminus. However, there was no difference in the potency of CGRP to increase cAMP production by these leucine mutant receptors when compared to wild type CLR, consistent with the notion that the neuropeptide C-terminal F37 is important for docking but not activation of the receptor. This observation was conserved when modified CGRP ligands lacking the amidated F37 demonstrated similar potencies to generate cAMP at both wild type and mutant CLRs. Furthermore, these modified CGRP ligands displayed a significant but similar loss of binding for all leucine mutant and wild type CLR because the important receptor contact on the neuropeptide was missing in all experimental situations.

conclusionThese results are consistent with previous structure-function investigations of the neuropeptide and are the first to propose specific CLR binding contacts for the amidated F37 of CGRP that are important for docking but not activation of the mature CGRP receptor.

Indexed as

Binding SitesCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinCells, CulturedCyclic AMPHumansModels, MolecularRadioligand AssayReceptors, CalcitoninStructure-Activity RelationshipCalcitonin Gene-Related PeptideCalcitonin Receptor-Like ProteinCALCRL protein, humanCyclic AMPReceptors, Calcitonin

Identifiers

PMID16776831
PMCPMC1525162
OpenAlexW2169854920

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.